Sel 10mg we yu de du

▎ Sel Struktrɔ

Sos: PubChem

Sikyɔn: TKPRPGP Mɔlikul Fɔmula: C 33H 57N 11O9 Molikul Weyt: 751,9 g/mol CAS Nɔmba: 129954-34-3 PubChem CID: 11765600, ɛn di ɔda wan dɛn Sinonim dɛn: Sel

▎ Sel Risach

Wetin na di risach bakgrɔn fɔ Sel?

Nyuroadapshɔn ɛn di Ɛndojɛnik Opioid Sistɛm: 

di εndojεnik opioid sistεm de involv insay di nyuroadaptεshכn prכsεs we di εksojen opioid dεm de kכz. Sel, wan anxiolytic we dεn sεntez bays pan di rεgεdyushכn pεptida tuftsin, kin inhεbit di aktvכti fכ εnkephalin-dεgradin εnzym dεm, so dat i de inkrεs di lεvεl fכ lכsin εnkεfalin insay di plasma (Nadorova AV, 2022). dis sho se Sel kin εksyεrt in ifekt dεm bay we i de rεgεl di εndojεnik opioid sistεm.

Wae pɔrsin de wɔri ɛn wae pɔrsin de fil na wan pan de prɔblɛm wae kin kam wit pɔrsin wae gɛt dis maynia sik na di wɔl. di klinik anxiolytic dכg dεm we dεn kin yus kin mεnli fכs pan di fכmakכlכjik rεguleshכn fכ di aktvכti fכ di bren in GABA rεsεpכta sistεm. Bɔt dɛn kayn drɔgs ya kin gɛt sɔm klinik prɔblɛm dɛn lɛk dipɛnshɔn ɛn mɛmori impairment (Vyunova TV, 2018). di rεkכgnishכn de inkrεs fכ di rol we nyuropεptida dεm εn bayoaktiv lipid dεm de ple na di pathophysiology fכ di mכd εn anxiety dizכrd. di heptapeptide Sel de sho lכng tεm anxiolytic εn nootropic ifekt dεm (Vyunova TV, 2018).

Wetin na di mɛkanism fɔ akshɔn fɔ Sel?

Wetin na di mɛkanism fɔ akshɔn fɔ Sel pan wɔri ɛn mud disɔda?

Rigulεt di GABA Risεptor Sistem: 

Wae yu de wɔri ɛn wae yu de fil bɔt yu maynd na de prɔblɛm wae kin kam wit yu maynd wɛl bɔdi ɔlsay na di wɔl. di klinik anxiolytic dכg dεm we dεn kin yus kin mεnli εksεrt dεn ifekt bay we dεn de rεgεl di aktiviti fכ di GABA rεsεpכta sistεm na di bren, bכt dεn kin gεt prכblεm lεk dipεndεns εn mεmכri impεryans. stכdi dεn dכn fכnshכn se di hεptapεptida Sel (Thr-Lys-Pro-Arg-Pro-Gly-Pro) gεt tεrapi ifekt pan anxiety εn mכd dizכrd. raydioligand-rεsεptor analisis mεtכd dεn sho se Sel de afekt [3H] GABA binding as positifu allosteric mכdulet. di kכmbayn akshכn fכ Sel wit sכm bεnzodiazepin dεm de rεgεl bak di [3H] GABA binding aktiviti in wan spεsifi k we. Dis ifekt nɔto aditiv ɛn i difrɛn frɔm we yu yuz ɛni wan pan dɛn tin ya nɔmɔ. Sel kin blok di rεgεdyushכn aktiviti dεm fכ dayazepam εn olanzapine. i tan lεk se di say we i de biεn difrεn frכm di wan dεm fכ dεn dεm ya, bכt i kin כvalap sכm pat ^[1] . so dεn spεkul se wan pan di mכlikul mεkanism dεm fכ Sel in anxiolytic ifekt kin riliyt to di sכbtayp-sεlektiv kכnsantreshכn-dipεndεnt allosteric rεguleshכn fכ GABA rεsεpכta dεm.

Wetin na di mεkanism fכ Sel fכ rεliv di analgesia we mכfin de indyuz?

Inhibiting Morphine Witdrawal Riakshɔn: 

sכm stכdi dεn sho se di pεptida sכbstans Sel kin wik di witdrawal riakshכn fכ rat to mכfin pan wan sכm dכz. fכ egzampl, insay di mכfin witdraw mכdel we nalokson indyuz, wan singl intrapεritכnial injεkshכn fכ Sel (0.3mg/kg) kin ridyus di tכtal indeks fכ di mכfin witdraw sεndrכm bay 39.6%, sכmtεm εliviet di simptom dεm lεk kכnvulsiv riakshכn, ptosis, εn postural dizכrd, εn inkrεs di taktil sεnsitiviti thrεshold fכ mכfin-dipεndεnt rat dεm bay 9 tɛm ^[2] . dis sho se Sel kin indaykt afekt di analgesic mεkanism fכ mכfin bay we i de rεgεl di nεv sistεm in dipεndεns pan mכfin.

Sinerjistik Analjɛsik Ifɛkt wit Mɔfin: 

Insay animal ɛkspiriɛns, risach pipul dɛn si se Sel de sho wan sinajɛstik analjɛsik ifɛkt we dɛn yuz am togɛda wit mɔfin. mכfin kin mek wan sכm digri fכ analgesia pan wan sכm doz, εn pan כl we Sel insεf nכ gεt klia analgesic ifekt, we dεn yuz am in kכmbayn wit mכfin pan wan spεsifi k doz (0.9mg/kg), i kin inkrεs di latεns fכ di mays in rεspכns to tεmral stimuli, εnhans di analgesic ifekt to 29.9% fכ di maksimal ifekt (MBE) ^[3] . dis sho se Sel kin εnhans di analgesic ifekt fכ mכfin tru wan sכm path.

Akt pan di Enkephalin Sistɛm: 

bays pan di stכdi fכ di fysiolojikal ifekt dεm fכ Sel εn in fragmεnt dεm, dεn spεkul se Sel de akt pan di nεtwכk fכ di kaskad prכsεs fכ pεptida dεm εn mεdiate dεm tru εnkεfalin. εnkephalin na wan kayn εndojεnik opioid pεptida εn i de ple imכtant rol fכ rεgεl di pen. sel kin afekt di analgesic ifekt fכ mכfin bay we i de rεgεl di aktvכti fכ di εnkεfalin-dεgrεd εnzym dεm εn i de inkrεs di lεvεl fכ lכsin εnkεfalin na di plasma ^[4]..

Efεkt dεm we Sel (0.3 mg/kg) gεt pan di rεkכgnishכn כf di nכvel כbjεkt in rat dεm we dεn sכbjεkt to fכs alkolכlayzeshn.

Sos:PubMed ^{[7] we dɛn pul am.}

Wetin na di pɔtnɛshɛl prinsipul fɔ Sel fɔ trit di wikɛd dizayd we de na di post-COVID sindrom?

Bays pan Immunomodulatory Efεkt dεm: 

We wi tink bɔt di men wok we di imyun dizayd dɛn de du fɔ mek di sik we dɛn kɔl COVID-19, i tan lɛk se drɔgs we gɛt imyunomodulatory ifɛkt dɛn go prɔmis fɔ trit di post-COVID sindrom. Sel na pεptida dכg we dεn kriya bays pan di immunomodulator tafcin. Insay di tritmɛnt fɔ di post-COVID syndrome, Sel kin pul di wikɛd simptom dɛm bay we i de rigul di imyun sistɛm ɛn kɔrɛkt di imyun sistɛm we nɔ de wok fayn. fכ egzampl, Sel kin gεt dayrekt aktiviti pan imyun intarakshכn כ akt indaykt bay we i de ridyus di post-strεs rispכns, we de mek i de mεnten di nכmal stet fכ imyun fכnshכn ^[5]..

Anxiolytic ɛn Improving Mood Disɔda dɛm: 

Insay di post-COVID syndrome, bɔku tɛm di sik pipul dɛn kin gɛt prɔblɛm wit dɛn maynd lɛk fɔ wɔri ɛn pwɛl at, we kin kam wit wikɛdnɛs ɛn nɔ kin wok fayn. Stɔdi dɔn sho se Sel kin pul di sayn dɛm fɔ wɔri ɛn pwɛl hat we dɛn de du di tritmɛnt. di mεkanism fכ akshכn we i de du kin riliyt to di rεguleshכn we Sel de du fכ di nyurotransmitta sistεm na di bren. fכ egzampl, Sel kin akt lεk positifu allosteric mכdulet fכ afekt [3H] GABA binding, we de rεgεl di aktvכti fכ di GABA rεsεpכta sistεm εn de εksyεrt wan anxiolytic ifekt ^[1]..

Nyuroprotɛktiv Ɛfɛkt: 

Insay di stɔdi, dɛn bin sheb di sik pipul dɛn to tu grup dɛn. Wan grup bin yuz wan nyuroprotɛktiv kɔmpleks (cholitilin, mexidol, milgamma) ɛn Sel, ɛn di ɔda grup bin yuz di nyuroprotɛktiv kɔmpleks nɔmɔ. Di risal sho se di pasɛnt dɛn we de yuz Sel bin gɛt bɛtɛ ifɛkt pan wikɛdnɛs ɛn dikɛd mental pefɔmɛns. dis de sho se Sel kin akt sinagεstik wit di nyuroprotεktiv kכmpleks fכ εksyεrt nyuroprotεktiv ifekt, so dat i de impruv di wikεd simptom dεm fכ di sik pipul dεm ^[5]..

Antivayrɔs Ifɛkt: 

Stɔdi dɔn sho se Sel gɛt antivayral prɔpati insay ɛkspirimɛnt inflɔɛnsa infɛkshɔn. Pan ɔl we naw, no dairekt pruf nɔ de fɔ se Sel gɛt antivayral ifɛkt agens di COVID-19 vayrɔs, we dɛn gi am di wok we i de du pan influenza vayrɔs infɛkshɔn, Sel kin gɛt sɔm impak pan di COVID-19 vayrɔs tru wan patikyula we, so dat i go ɛp fɔ trit di wiknɛs dizayd we de na di post-COVID sindrom. fכ egzampl, insay in vivo stכdi dεm, Sel indyuz di jin εksprεshכn fכ intafεron-α (IFN-α), we kin εp fכ εnhans di bכdi in antivayral abiliti ^[6]..

Wetin na di ifɛkt dɛn we Sel gɛt?

Anxiolytic ɛn Improving Mood Disɔda dɛm: 

Insay di post-COVID syndrome, bɔku tɛm di sik pipul dɛn kin gɛt prɔblɛm wit dɛn maynd lɛk fɔ wɔri ɛn pwɛl at, we kin kam wit wikɛdnɛs ɛn nɔ kin wok fayn. Stɔdi dɔn sho se Sel kin pul di sayn dɛm fɔ wɔri ɛn pwɛl hat we dɛn de du di tritmɛnt. di mεkanism fכ akshכn we i de du kin riliyt to di rεguleshכn we Sel de du fכ di nyurotransmitta sistεm na di bren. fכ egzampl, Sel kin akt lεk positifu allosteric mכdulet fכ afekt [3H] GABA binding, we de rεgεl di aktvכti fכ di GABA rεsεpכta sistεm εn de εksyεrt wan anxiolytic ifekt ^[1]..

Nyuroprotɛktiv Ɛfɛkt:

Insay di stɔdi, dɛn bin sheb di sik pipul dɛn to tu grup dɛn. Wan grup bin yuz wan nyuroprotɛktiv kɔmpleks (cholitilin, mexidol, milgamma) ɛn Sel, ɛn di ɔda grup bin yuz di nyuroprotɛktiv kɔmpleks nɔmɔ. Di risal sho se di pasɛnt dɛn we de yuz Sel bin gɛt bɛtɛ ifɛkt pan wikɛdnɛs ɛn dikɛd mental pefɔmɛns. dis de sho se Sel kin akt sinagεstik wit di nyuroprotεktiv kכmpleks fכ εksyεrt nyuroprotεktiv ifekt, so dat i de impruv di wikεd simptom dεm fכ di sik pipul dεm ^[5]..

Rilivin Analgesia we Mɔfin kin mek: 

sכm stכdi dεn sho se Sel, wan anxiolytic we dεn sεntez bays pan di rεgεdyushכn pεptida tuftsin, gεt impak pan mכfin-indyus analgesia in animal mכdel dεm. fכ egzampl, we di mכfin dכz na 3.0mg/kg (intraperitoneal injεkshכn), i kin mek antinocisepshכn, wit maksimal posεbul ifekt (MBE) we na 9%. pan tap we di Sel doz we na 0.9mg/kg nכ gεt antinociceptiv ifekt bay insεf, we dεn prε-trit am wit mכfin, i kin inkrεs di laytεnt riakshכn tεm εn mek antinociceptiv ifekt fכ 29.9% MBE ^[3]..

Fɔ Alɛviet di Aversiv Simptom dɛm we de mek pɔsin pul di mɔfin: 

di aktvכti fכ di pεptida tuftsin analכg Sel bin stכdi in wan mכfin witdraw mכdel we nalokson indyuz. wan singl intraperitoneal injεkshכn fכ Sel pan wan anxiolytic doz we na 0.3mg/kg kin ridyus di tכtal indeks fכ di mכfin witdrawal sεndrכm bay 39.6%, sכmtεm (p30.0001) εliviet kכnvulsiv riakshכn, ptosis, εn postural dizכrd, εn inkrεs di taktil sεnsitiviti thrεshold fכ mכfin-dipεndεnt rat dεm bay 9 tεm we dεn kכmpεr wit di pɔsitiv kɔntrol grup. na di sem tεm, Sel sכmtεm infεriכs to dayazepam pan dכz 2mg/kg in tεm dεm fכ fכmakכlכjik aktiviti (dεn de ridyus di tכtal indeks fכ di mכfin witdrawal sεndrכm bay 49.3% εn inkrεs di sεnsitiviti trεshold bay 13 tεm). So, lεk dayazepam, Sel kin εliviet di aversiv simptom dεm fכ mכfin witdraw in opioid dipεndεns in rat ^[2]..

Fɔ mek yu nɔ ebul fɔ mɛmba tin we ɛtɛnol de mek: 

insay rat dεm we gεt 10% εtanכl as dεn wan ol likwid sכs fכ te 30 wik, dεn invεstigat di ifekt dεm we Sel, we na pεptida-bεys anxiolytic drog we dεn sεntez frכm di εndojεnik pεptida tuftsin, gεt pan mεmכri impεryans εn bren-dεriv nyurotrofik fכktכ (BDNF) lεvεl dεm. In objek rεkכgnishכn tεst, Sel sho kכgnitiv-εnhans ifekt in 9 mכnt ol rat dεm we nכ εkspos to εtanכl εn i prεvεnt di divεlכpmεnt כf εtanכl-indyus mεmכri εn atεnshכn impεryans we dεn de pul alkol. in vitro εkspεriεns sho se Sel kin inhεbit εtanכl-indyus inkrεs pan BDNF lεvεl dεm na di hipokampus εn prεfrכnt kכtεks. frכm di tin dεm we wi bin dכn du, wi kin kכnklud se dis sinaptojεnik ejen gεt fayn ifekt pan εj-rεlatεd mεmכri impεryans we de asai wit krכnik alkol dipεndεns, εn kכnfכm se BDNF-rεlatεd nyurotrofik mεkanism dεm de involv insay di mεkanism fכ akshכn fכ Sel ^[7]..

Tritmɛnt fɔ di Pɔst-COVID-19 Sindrom: 

Pɔst-COVID-19 sindrom kin apin afta COVID-19 infɛkshɔn ɛn dɛn kin si am bak pan kes dɛm we gɛt mild ɔ asymptomatic sik. di mכst kכmכn simptom dεm fכ di brij sεndrכm na fכ taya εn fכnshכnal dεklin, dεn de fala di kכgnitiv impεryans. giv di sentral rol we di imyun disrεgulεshכn de ple fכ di patכjεnεsis fכ COVID-19, imyunomodulεtכri drog dεm wit dairekt imyun-mכdulεshכn ifekt כ dεn wan dεm we indaykt mεnten imyun fכnshכn bay we dεn de ridyus di post-strεs rεspכns dεm de hכl pכtεnshal tεrapi prכmis.

Sel na pεptida dכg we dεn divεlכp bays pan di immunomodulator tafcin, we de wok fayn fכ trit difrεn nyuroz dεm εn dizכrd dεm we lεk nyurosis. We dɛn yuz am pan 2-3 drɔp 4 tɛm insay di de fɔ 30 dez kɔnsɛkutiv, Sel gɛt gud tritmɛnt ifɛkt pan pasɛnt dɛn we taya ɛn we nɔ gɛt bɛtɛ kɔgnitiv. Dɛn kin si bak fɔ mek yu nɔr de wɔri ɛn pwɛl hat sik ^{[5] .}.

Kɔrɛkt di kɔgnitiv ɛn imɔshɔnal disɔda pan pasɛnt dɛn we gɛt atɔpik dɛmatitis: Wan stɔdi bin analayz di kɔgnitiv ɛn imɔshɔnal disɔda insay 65 pasɛnt dɛn we gɛt atɔpik dɛmatitis (AD) ɛn randomly divayd di pasɛnt dɛn to tu grup dɛn we dɛn kin kɔmpia wit stɛtistik.

Di fɔs grup pan di pasɛnt dɛn bin gɛt standad drɔg tɛrapi fɔ atɔpik dɛmatitis (BT), we di sɛkɔn grup bin gɛt wan kɔmbaynshɔn fɔ serank ɛn BT via intranasal administreshɔn (S + BT), we dɛn gi tri tɛm ɛvride, wit tu drɔp we dɛn put insay ɛni nos fɔ ɛni doz, fɔ wan totɛl we na 14 dez. Di kɔntrol grup bin gɛt 30 pipul dɛn we gɛt wɛlbɔdi. Pɔsin in wɔri (LT), riaktiv wɔri (RT), yohimbine lɛvɛl, blɔd β-ɛndɔrfin lɛvɛl, ɛn kwaliti ɔf layf (QOL) bin asɛs bifo tritmɛnt ɛn 30 dez afta di tritmɛnt bigin.

Di stכdi risכlt sho se di RT lεvεl na AD pasεnshכn bin 4.2 tεm hכy pas di wan dεm na di kכntrol grup, LT lεvεl bin 3.2 tεm hכy, εn ykhtumia lεvεl bin 18 tεm hכy. Insay di BT grup, RT dכn dכn bay 1.4 tεm εn LT dכn dכn bay 1.3 tεm 30 dez afta dεn bigin tritmεnt. In di C+BT grup, di dεkrεshכn dεm na LT εn RT bin sכm kayn sכmtin, כl tu bay 2.4 tεm.

No signifyant chenj nɔ bin de pan di yekutumia simptom ɔ β-ɛndɔrfin lɛvɛl na di blɔd fɔ di pasɛnt dɛn na di BT grup. Insay di S+BT grup, di Alexis imɔshɔnal dizayd dεm dכn dכn bay 1.2 tεm, εn di β-εndorfin lεvεl dεm na di bכdi inkrεs bay 1.9 tεm. Di kwaliti ɔf layf indeks fɔ di pasɛnt dɛn na di BT grup bin go dɔŋ bay 1.2 tɛm 30 dez afta dɛn bigin di tritmɛnt, we di wan fɔ di pasɛnt dɛn we bin de na di S+BT grup bin go dɔŋ bay 1.7 tɛm. Di kɔnklushɔn na dat di ɛlevɛt lɛvɛl fɔ pɔsin in yon wɔri, riaktiv wɔri, ɛn yekhtumia pan AD pasɛnt dɛn de ridyus dɛn kwaliti fɔ layf. di yus fכ di rεgεdyushכn pεptida Sel insay di kכmprεhεnsiv tritmεnt fכ AD pasεnshכn dεm gεt kכrεktiv ifekt pan imyushכnal εn kכgnitiv dizכrd, rεdכks di lεvεl dεm fכ pasכnal anxiety, riaktiv anxiety, εn yekhtumia, inkrεs di lεvεl dεm fכ β-εndorphin na di bכdi, εn impruv di pasεnshכn kwaliti כf layf ^[8]..

fכ kכnklud, as sεntetik pεptida dכg we dεn divεlכp bays pan di nεchכral pεptida kכlכsterin, Sel dεn sho mכlti-dimεnshכnal aplikεshכn pכtεnshal in klinik prεktis εn risεch. I kɔr valyu de fɔ gi nyu sɔlvishɔn fɔ sik dɛm lɛk wɔri prɔblɛm, strɛs-rilayt dizayd, mɛmori impairment, ɛn imyun dizayd bay we i de rigul di nyurotransmitta sistɛm, ɛp fɔ mek di imyun wok fayn, ɛn fɔ mek di kɔgnitiv wok fayn. Klinik stɔdi dɔn kɔnfyus se Sel kin rili rilivu di simptom dɛm fɔ wɔri ɛn pwɛl hat, impruv di wikɛdnɛs ɛn kɔgnitiv dizayd dɛm na post-COVID sindrom, ɛn sinajɛstik wan ɛnhans di anti-inflammatory ifɛkt na di tritmɛnt fɔ atopic dɛmatitis. We yu kɔmpia am wit tradishɔnal drɔgs, i nɔ gɛt bɔku sayd ɛfɛkt, i kin tek lɔng tɛm fɔ du am, ɛn i de sho spɛshal bɛnifit dɛn pan di tin dɛn we gɛt fɔ du wit analjɛsia, anti-adikshɔn, ɛn nyuroprotɛkshɔn.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Vyunova TV na wan Rɔshian nyurokɛmist, kemist, bayolojist, ɛn risachɔ. I dɔn mek bɔku kɔntribyushɔn to di fild dɛm fɔ bayɔkemistri & mɔlikul bayoloji, kemistri, bayɔfiziks, famakɔlɔji & famasi, ɛn fisiɔlɔji. Vyunova dɔn gɛt fɔ du wit big big institiushɔn dɛn lɛk di Nashɔnal Risach Sɛnta 'Kurchatov Instityut' ɛn di Rɔshian Akademi fɔ Sayns. Di risach we Vyunova dɔn du dɔn mek i gɛt bɔku patɛnt dɛn bak, we sho se i gɛt nyu we fɔ sɔlv sayɛns prɔblɛm dɛn. Di we aw i de wok tranga wan fɔ mek pipul dɛn no mɔ bɔt in wok dɔn mek pipul dɛn rɛspɛkt am na di sayɛns kɔmyuniti. Vyunova TV de na di list insay di rɛfrɛns fɔ saytayshɔn [1].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Pεptid-Bεys Anxiolytics: Di Mכlikul Aspεkt dεm fכ Hεptapεptida Sεl Bayolojikal Aktiviti. PROTIN PƐPTAYD LƐT 2018; 25(10): 914-23.DOI:10.2174/0929866525666 18092514464 2. Di wan dɛn we de wok fɔ di gɔvmɛnt.

[2] Konstantinopolski M. A., Chεrnyakova IV, Kolik L. G., ɛn ɔda pipul dɛn. Sel, wan Pεptid Analog fכ Tuftsin, Attenuates Aversiv Sayn dεm fכ Morfin Widdrawal in Rat. B EXP BAYƆL MED+ 2022; 173(6): 730-3.DOI: 10.1007/s10517-022-05624-x.

[3] Nadorova A. V., Chεrnyakova IV, Kolik L. G., ɛn ɔda pipul dɛn. Sel ifekt pan mכfin-indyuz analgesia in vivo εkspεriεns. Famakokinɛtiks ɛn Famakodaynamiks 2022.

DOI: https://api.semanticscholar.org/KɔpɔsID:248608989. Di wan dɛn we de stɔdi bɔt di Baybul.

[4] Koroleva S. V., Mjasoedov N. F., ɛn ɔda pipul dɛn. Fisiolojikal Efεkt dεm fכ Sel εn in Fragmεnt dεm. BAYƆL BƆL+ 2019; 46 (4): 407-14.DOI: 10.1134/S1062359019040071.

[5] Pogodina M, Nikiforova E. Pɔst-COVID Sindrom: Pɔsibiliti fɔ Tɛrapi fɔ Astɛnik Disɔda wit Sel. Vrach we de na di wɔl 2024.

DOI: https://api.semanticscholar.org/KɔpɔsID:270168582. Di wan dɛn we de stɔdi bɔt di Baybul.

[6] Ershov F. I., Uchakin P. N., Uchakina O. N., M ɛ zentseva M. V., Alɛksɛev L. A., Myasoyedov N. F.. Antivayral aktvכti fכ immunomodulator Sel in εkspεriεns influenza infεkshכn. Voprosy Vayrɔsɔlɔjii 2009; 54(5): 19-24.

[7] Kolik L. G., Nadorova A. V., Antipova T. A., Kruglov S. V., Kudrin V. S., Durnev A. D., ɛn ɔda pipul dɛn. Sel, Pεptid Analog fכ Tuftsin, Protekt Agens Ethanol-Induse Mεmכri Impεryans bay Rεgulεt BDNF Kכntεnt in di Hippocampus εn Prεfrכnt Kכtεks in Rat. B EXP BIOL MED+ 2019 we de na di wɔl; 167(5): 641-4.DOI: 10.1007/s10517-019-04588-9.

[8] Kruglova L. S., Novikova L. A., Dontsova E. V., Borzunova L. N., Kova N. V., ɛn ɔda pipul dɛn. Posisibul dεm fכ kכrekshכn kכgnitiv-afεktiv dizכrd in pasεnshכn dεm wit atכpik dεmatitis we de yuz selanc rεgεdyushכn pεptida. Курский научно -практический вестник « Человек и его здоровье » 2020.

https://api.semanticscholar.org/CorpusID:234612442. https://pubmed.ncbi.nlm.nih.gov/19882898/ Di wan dɛn we de stɔdi bɔt dis sik.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.